Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia
Authors
Keywords
-
Journal
PLoS One
Volume 8, Issue 11, Pages e80070
Publisher
Public Library of Science (PLoS)
Online
2013-11-15
DOI
10.1371/journal.pone.0080070
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas
- (2013) J. Shortt et al. BLOOD
- Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: Old targets new hope
- (2013) Pradip De et al. CANCER TREATMENT REVIEWS
- The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line
- (2012) Hongyun Xing et al. LEUKEMIA RESEARCH
- BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
- (2011) S. Soverini et al. BLOOD
- Novel Phosphoinositide 3-Kinase/mTOR Dual Inhibitor, NVP-BGT226, Displays Potent Growth-Inhibitory Activity against Human Head and Neck Cancer Cells In Vitro and In Vivo
- (2011) K.-Y. Chang et al. CLINICAL CANCER RESEARCH
- Research and innovation in the development of everolimus for oncology
- (2011) David Lebwohl et al. Expert Opinion on Drug Discovery
- BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
- (2011) Hilmar Quentmeier et al. Journal of Hematology & Oncology
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer
- (2011) Roman Nawroth et al. PLoS One
- Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia
- (2010) N. Chapuis et al. CLINICAL CANCER RESEARCH
- Second AKT: The rise of SGK in cancer signalling
- (2010) Maressa A. Bruhn et al. GROWTH FACTORS
- Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
- (2010) Matthew R Janes et al. NATURE MEDICINE
- Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy
- (2010) C A Sparks et al. ONCOGENE
- Optimal targeting of the mTORC1 kinase in human cancer
- (2009) Heidi A Lane et al. CURRENT OPINION IN CELL BIOLOGY
- mTOR and cancer: many loops in one pathway
- (2009) Alejo Efeyan et al. CURRENT OPINION IN CELL BIOLOGY
- Chronic myeloid leukemia and BCR/ABL signal pathways are not associated with AKT1 pleckstrin homology domain (E17K) mutations
- (2009) Yanli He et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Long–term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors
- (2009) Bart A. Nijmeijer et al. EXPERIMENTAL HEMATOLOGY
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
- (2009) Carson C. Thoreen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting the mTOR Signaling Network for Cancer Therapy
- (2009) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition
- (2009) M. Breuleux et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Molecular mechanisms of mTOR-mediated translational control
- (2009) Xiaoju Max Ma et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines
- (2008) D. S. Levy et al. BLOOD
- The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias
- (2008) I S Mahmoud et al. BRITISH JOURNAL OF CANCER
- Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement
- (2008) Joerg Baeumler et al. CANCER GENETICS AND CYTOGENETICS
- Mammalian target of rapamycin as a therapeutic target in oncology
- (2008) Robert T Abraham et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells
- (2008) Michael G. Kharas et al. JOURNAL OF CLINICAL INVESTIGATION
- PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability
- (2008) Ana Silva et al. JOURNAL OF CLINICAL INVESTIGATION
- Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation
- (2008) Cristina Montiel-Duarte et al. LEUKEMIA RESEARCH
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now